All In Biotech

Drug Trial Radar · NCT04966559

Effects of a Peripherally Acting µ-opioid Receptor Antagonist on Recurrent Acute Pancreatitis

Effects of a Peripherally Acting µ-opioid Receptor Antagonist on Recurrent Acute Pancreatitis An Investigator-initiated, Randomized, Placebo-controlled, Double-blind Clinical Trial

Last checked: Nov 20, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

74

Actual

Start

Jan 12, 2022

Primary completion

Mar 30, 2024

Study completion Jun 1, 2024

Sponsor

Lead sponsor
Asbjørn Mohr DrewesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Odense University Hospital; Hvidovre University Hospital; University Hospital Bispebjerg and Frederiksberg; Karolinska University Hospital
First posted
Jul 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the effect of a peripheral acting opioid antagonist (PAMORA) on the disease course of patients with recurrent acute inflammation of the pancreas (acute pancreatitis). The study will be conducted by treating outpatients suffering from recurrent acute pancreatitis with a PAMORA (naldemedine) for 12 months.

Conditions

  • Pancreatitis, Acute

Interventions

  • Placebo treatmentDrug

    Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.

  • Naldemedine 0.2 MG Oral TabletDrug

    Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of AP attacks verified by the Atlanta CriteriaTime frame: Observation period starts from day of randomization and ends after a minimum of 6 months and a maximum of 12 months

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Digestive Disease Center K, Bispebjerg University Hospital

    Bispebjerg, Denmark

  • Gastrounit, Hvidovre University Hospital

    Hvidovre, Denmark

  • Odense Pancreas Center

    Svendborg, Denmark

  • Mech-Sense, Department of Medical Gastroenterology, Aalborg University Hospital

    Aalborg, Jutland, Denmark

  • Karolinska University Hospital

    Stockholm, Solna (l1:00), Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.